SINOMED(688108)2024-11-01 08:07Financial Performance - The company achieved a revenue of 318 million CNY in the first three quarters of 2024, representing a year-on-year growth of 30.2% [1] - The net profit attributable to shareholders was -6.74 million CNY, while the net cash flow from operating activities was 49.72 million CNY, showing a year-on-year increase of 37.18% [1] Product Development and Market Performance - The Nova stent's sales volume in the first three quarters approached the total sales of the previous year, indicating a steady growth despite not winning bids in the "3+N" procurement in Hebei [2] - The company maintains a stable pricing strategy for the Nova stent, considering both domestic and international market prices for future products like the self-expanding drug-eluting stent [2] - The revenue distribution for coronary and neuro-interventional products in the first three quarters was approximately 55% and 45%, respectively [4] Research and Development - The company has consistently maintained a high proportion of R&D investment, focusing on innovative products in the neuro-interventional field [3] - R&D expenses increased by approximately 5-6 million CNY in the third quarter, driven by clinical trials and product registrations [6] - Future R&D investments will focus on high-value products, with a potential decrease in R&D expenditure as revenue grows [6] Regulatory and Market Strategy - The company is in the process of registering the mesh stent, with expectations to obtain approval next year [3] - The company is actively preparing for the commercialization of the self-expanding stent, with a robust sales team in place [6] - The FDA submission for coronary stents is progressing smoothly, with expectations to submit final materials soon, which will enhance production processes and cost efficiency [5]